Sung Ho HahmCEO at Rophibio Inc.
Dr. Hahm received Ph.D. degree in biomedical science from Univ South Carolina followed by Postdoctoral training at National Institutes of Health and Staff Fellow at Johns Hopkins Medical School. He has been working as CEO of Rafagen in USA and then as the Founder and CEO of Rophibio in Korea. He has accumulated over 25 years of experience in cellular and molecular biology research and development. At Rophibio, he has been leading technology development in CHO cell-based cell line development and upstream process development for the company’s biosimilars and biopharmaceuticals candidates.